Dianthus Therapeutics Inc Financials

DNTH

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Dianthus Therapeutics Inc (DNTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 75/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Dianthus Therapeutics Inc has an operating margin of -1633.7%, meaning the company retains $-1634 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -1704.7% the prior year.

Growth

100

Dianthus Therapeutics Inc's revenue surged 120.6% year-over-year to $6.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

100

Dianthus Therapeutics Inc carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 15.22, Dianthus Therapeutics Inc holds $15.22 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Piotroski F-Score Weak

3/9

Dianthus Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, Dianthus Therapeutics Inc generates $0.92 in operating cash flow (-$78.2M OCF vs -$85.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

$6.2M

YoY+120.6%

Dianthus Therapeutics Inc generated $6.2M in revenue in fiscal year 2024. This represents an increase of 120.6% from the prior year.

EBITDA

-$101.8M

YoY-111.5%

Dianthus Therapeutics Inc's EBITDA was -$101.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 111.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$85.0M

YoY-95.1%

Dianthus Therapeutics Inc reported -$85.0M in net income in fiscal year 2024. This represents a decrease of 95.1% from the prior year.

EPS (Diluted)

$-2.55

YoY+69.8%

Dianthus Therapeutics Inc earned $-2.55 per diluted share (EPS) in fiscal year 2024. This represents an increase of 69.8% from the prior year.

Cash & Debt

$22.8M

YoY-82.8%

5Y CAGR-18.9%

Dianthus Therapeutics Inc held $22.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

$0.00

Dianthus Therapeutics Inc paid $0.00 per share in dividends in fiscal year 2024.

Shares Outstanding

31M

YoY+110.0%

Dianthus Therapeutics Inc had 31M shares outstanding in fiscal year 2024. This represents an increase of 110.0% from the prior year.

Gross Margin

N/A

Operating Margin

-1633.7%

YoY+70.9pp

Dianthus Therapeutics Inc's operating margin was -1633.7% in fiscal year 2024, reflecting core business profitability. This is up 70.9 percentage points from the prior year.

Net Margin

-1362.8%

YoY+178.4pp

Dianthus Therapeutics Inc's net profit margin was -1362.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 178.4 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$87.9M

YoY+167.7%

5Y CAGR+8.2%

Dianthus Therapeutics Inc invested $87.9M in research and development in fiscal year 2024. This represents an increase of 167.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

DNTH Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$6.2M+120.6%	$2.8M-56.0%	$6.4M+334.8%	$1.5M	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$87.9M+167.7%	$32.8M+11.8%	$29.4M+133.1%	$12.6M-75.1%	$50.6M-14.5%	$59.2M
SG&A Expenses	$25.0M+37.6%	$18.2M+169.3%	$6.7M+244.7%	$2.0M-93.0%	$28.1M+18.2%	$23.8M
Operating Income	-$101.9M-111.5%	-$48.2M-62.2%	-$29.7M-127.0%	-$13.1M+83.4%	-$78.7M+5.1%	-$83.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$85.0M-95.1%	-$43.6M-53.0%	-$28.5M-117.2%	-$13.1M+82.5%	-$74.9M+2.4%	-$76.8M
EPS (Diluted)	$-2.55+69.8%	$-8.45	$-32.57-117.0%	$-15.01-777.8%	$-1.71	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'23	Q3'24	Q4'22	Q4'21
Revenue	$396K+105.2%	$193K-83.4%	$1.2M	N/A	$924K	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$32.5M+23.8%	$26.3M-2.8%	$27.0M	N/A	$8.0M-22.4%	$10.3M	N/A	N/A
SG&A Expenses	$8.2M-7.6%	$8.9M+20.9%	$7.3M	N/A	$8.7M+250.0%	$2.5M	N/A	N/A
Operating Income	-$40.3M-15.3%	-$34.9M-5.3%	-$33.2M	N/A	-$15.8M-33.8%	-$11.8M	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$36.8M-16.2%	-$31.6M-7.2%	-$29.5M	N/A	-$14.8M-32.5%	-$11.1M	N/A	N/A
EPS (Diluted)	$-0.97-10.2%	$-0.88-7.3%	$-0.82	N/A	$-3.78	$-12.73	N/A	N/A

DNTH Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$374.0M+108.5%	$179.4M+115.9%	$83.1M+779.4%	$9.5M-94.2%	$161.6M+0.1%	$161.5M
Current Assets	$280.9M+58.3%	$177.5M+116.3%	$82.0M+773.8%	$9.4M-93.8%	$151.5M+1.1%	$149.8M
Cash & Equivalents	$22.8M-82.8%	$132.3M+761.2%	$15.4M+101.2%	$7.6M-86.9%	$58.2M-10.6%	$65.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$294K-93.7%	$4.7M+902.1%	$469K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.5M+104.4%	$10.5M-91.7%	$127.5M+377.4%	$26.7M-83.9%	$165.8M+716.0%	$20.3M
Current Liabilities	$18.5M+91.6%	$9.6M+17.1%	$8.2M+53.7%	$5.4M-53.2%	$11.4M-19.0%	$14.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$352.5M+108.7%	$168.9M+480.6%	-$44.4M-157.2%	-$17.2M-310.4%	-$4.2M-103.0%	$141.2M
Retained Earnings	-$174.4M-95.0%	-$89.4M-95.0%	-$45.9M-163.7%	-$17.4M+93.2%	-$254.4M-41.7%	-$179.5M

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'23	Q3'24	Q4'22	Q4'21
Total Assets	$577.4M+77.1%	$326.1M-6.5%	$348.6M+94.3%	$179.4M-6.8%	$192.5M+144.7%	$78.6M-5.4%	$83.1M+779.4%	$9.5M
Current Assets	$413.8M+57.0%	$263.6M-2.7%	$271.0M+52.7%	$177.5M-7.3%	$191.5M+143.5%	$78.6M-4.1%	$82.0M+773.8%	$9.4M
Cash & Equivalents	$56.0M+322.9%	$13.2M+30.9%	$10.1M-92.4%	$132.3M-15.9%	$157.3M+290.5%	$40.3M+162.2%	$15.4M+101.2%	$7.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$5.0M+12720.5%	$39K-96.1%	$1.0M+240.1%	$294K+26.7%	$232K	N/A	$4.7M+902.1%	$469K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$31.0M+34.8%	$23.0M+15.1%	$20.0M+89.6%	$10.5M-25.2%	$14.1M-89.9%	$140.1M+9.9%	$127.5M+377.4%	$26.7M
Current Liabilities	$23.9M+18.7%	$20.1M+18.5%	$17.0M+76.0%	$9.6M-26.4%	$13.1M+224.2%	$4.0M-51.0%	$8.2M+53.7%	$5.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$546.5M+80.3%	$303.1M-7.8%	$328.6M+94.6%	$168.9M-5.3%	$178.4M+390.2%	-$61.5M-38.5%	-$44.4M-157.2%	-$17.2M
Retained Earnings	-$272.3M-15.6%	-$235.5M-15.5%	-$203.9M-128.0%	-$89.4M-13.4%	-$78.9M+81.8%	-$434.5M-847.2%	-$45.9M-163.7%	-$17.4M

DNTH Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$78.2M-112.1%	-$36.9M-26.8%	-$29.1M-193.5%	-$9.9M+84.5%	-$64.0M-12.1%	-$57.1M
Capital Expenditures	N/A	N/A	$314K-75.2%	$1.3M+216.0%	$400K-86.9%	$3.1M
Free Cash Flow	N/A	N/A	-$29.4M-163.1%	-$11.2M+82.7%	-$64.4M-7.1%	-$60.2M
Investing Cash Flow	-$286.8M-1516.1%	$20.3M+133.9%	-$59.8M-181169.7%	-$33K+99.7%	-$10.6M-794.2%	$1.5M
Financing Cash Flow	$255.6M+91.4%	$133.6M+38.2%	$96.7M+548.3%	$14.9M-78.0%	$67.7M+8.7%	$62.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'23	Q3'24	Q4'22	Q4'21
Operating Cash Flow	-$30.6M-27.9%	-$23.9M+13.5%	-$27.6M-133.1%	-$11.9M-18.6%	-$10.0M-111.2%	-$4.7M+46.5%	-$8.9M-126.1%	$33.9M
Capital Expenditures	N/A	N/A	N/A	N/A	$158K	$0	$0-100.0%	$15K
Free Cash Flow	N/A	N/A	N/A	N/A	$16.2M+442.8%	-$4.7M+46.5%	-$8.9M-126.1%	$33.9M
Investing Cash Flow	-$201.3M-861.1%	$26.4M+78.8%	$14.8M+279.6%	-$8.2M+28.4%	-$11.5M-152.6%	$21.9M+272.6%	-$12.7M+76.5%	-$53.8M
Financing Cash Flow	$274.5M+48229.8%	$568K+252.8%	$161K+103.3%	-$4.9M-103.5%	$138.4M	$0	$0+100.0%	-$74.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DNTH Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1633.7%+70.9pp	-1704.7%-1241.8pp	-462.9%+423.7pp	-886.6%	N/A	N/A
Net Margin	-1362.8%+178.4pp	-1541.2%-1097.5pp	-443.8%+444.4pp	-888.1%	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-22.7%+1.6pp	-24.3%+10.0pp	-34.3%+104.4pp	-138.7%-92.3pp	-46.4%+1.2pp	-47.5%
Current Ratio	15.22-3.2	18.43+8.5	9.97+8.2	1.75-11.5	13.26+2.6	10.62
Debt-to-Equity	0.060.0	0.06+2.9	-2.87-1.3	-1.55+37.9	-39.45-39.6	0.14
FCF Margin	N/A	N/A	-457.9%+298.7pp	-756.6%	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'23	Q3'24	Q4'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-10173.7%+7923.1pp	-18096.9%-15244.2pp	-2852.7%	N/A	-1705.5%	N/A	N/A	N/A
Net Margin	-9284.1%+7104.0pp	-16388.1%-13850.6pp	-2537.5%	N/A	-1597.7%	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-6.4%+3.3pp	-9.7%-1.2pp	-8.5%	N/A	-7.7%+6.5pp	-14.2%	N/A	N/A
Current Ratio	17.35+4.2	13.12-2.9	15.99-2.4	18.43+3.8	14.64-4.9	19.49+9.5	9.97+8.2	1.75
Debt-to-Equity	0.06-0.0	0.08+0.0	0.060.0	0.06-0.0	0.08+2.4	-2.28+0.6	-2.87-1.3	-1.55
FCF Margin	N/A	N/A	N/A	N/A	1382.5%	N/A	N/A	N/A

Similar Companies

Tourmaline Bio TRML

$1.2B

Zymeworks ZYME

$1.8B

Enliven Therapeutics Inc ELVN

$1.6B

Amylyx Pharmaceuticals AMLX

$1.5B

Intellia Therape NTLA

$1.5B

Frequently Asked Questions

What is Dianthus Therapeutics Inc's annual revenue?

Dianthus Therapeutics Inc (DNTH) reported $6.2M in total revenue for fiscal year 2024. This represents a 120.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Dianthus Therapeutics Inc's revenue growing?

Dianthus Therapeutics Inc (DNTH) revenue grew by 120.6% year-over-year, from $2.8M to $6.2M in fiscal year 2024.

Is Dianthus Therapeutics Inc profitable?

No, Dianthus Therapeutics Inc (DNTH) reported a net income of -$85.0M in fiscal year 2024, with a net profit margin of -1362.8%.

What is Dianthus Therapeutics Inc's earnings per share (EPS)?

Dianthus Therapeutics Inc (DNTH) reported diluted earnings per share of $-2.55 for fiscal year 2024. This represents a 69.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Dianthus Therapeutics Inc's EBITDA?

Dianthus Therapeutics Inc (DNTH) had EBITDA of -$101.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Dianthus Therapeutics Inc's operating margin?

Dianthus Therapeutics Inc (DNTH) had an operating margin of -1633.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Dianthus Therapeutics Inc's net profit margin?

Dianthus Therapeutics Inc (DNTH) had a net profit margin of -1362.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Dianthus Therapeutics Inc's operating cash flow?

Dianthus Therapeutics Inc (DNTH) generated -$78.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Dianthus Therapeutics Inc's total assets?

Dianthus Therapeutics Inc (DNTH) had $374.0M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Dianthus Therapeutics Inc spend on research and development?

Dianthus Therapeutics Inc (DNTH) invested $87.9M in research and development during fiscal year 2024.

How many shares does Dianthus Therapeutics Inc have outstanding?

Dianthus Therapeutics Inc (DNTH) had 31M shares outstanding as of fiscal year 2024.

What is Dianthus Therapeutics Inc's current ratio?

Dianthus Therapeutics Inc (DNTH) had a current ratio of 15.22 as of fiscal year 2024, which is generally considered healthy.

What is Dianthus Therapeutics Inc's debt-to-equity ratio?

Dianthus Therapeutics Inc (DNTH) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dianthus Therapeutics Inc's return on assets (ROA)?

Dianthus Therapeutics Inc (DNTH) had a return on assets of -22.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Dianthus Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Dianthus Therapeutics Inc (DNTH) had $22.8M in cash against an annual operating cash burn of $78.2M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Dianthus Therapeutics Inc's Piotroski F-Score?

Dianthus Therapeutics Inc (DNTH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dianthus Therapeutics Inc's earnings high quality?

Dianthus Therapeutics Inc (DNTH) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Dianthus Therapeutics Inc?

Dianthus Therapeutics Inc (DNTH) scores 75 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.